ArticleJournal of cachexia, sarcopenia and muscle2025
Plasma Extracellular Vesicles Biomarkers Linked to Lower Muscle Mass, Function and Physical Performance in Sarcopenia.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Review
- Myokines in exercise‑mediated bone homeostasis: Molecular signaling mechanisms and therapeutic implications for bone disorders (Review).International journal of molecular medicine · 2026Review
- Novel biomarkers for sarcopenia: a narrative review.Journal of orthopaedic surgery and research · 2026Review
- The crossroads between osteosarcopenia and intrinsic capacity-a narrative review.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Review
- The Role of Extracellular Vesicles MicroRNAs in Sarcopenia: From Aging to Multi-Morbidity.Aging medicine (Milton (N.S.W)) · 2026Review
- Distinct Proteomic Signatures Driving Progression of Sarcopenia: A Longitudinal Multicohort Study.Journal of cachexia, sarcopenia and muscle · 2026Article
- Ribosome Biogenesis and Translational Control in Skeletal Muscle Atrophy and Hypertrophy: Mechanisms and Therapeutic Perspectives.Biomolecules · 2026Review
- Extracellular vesicles at the neuromuscular junction: messengers of synaptic health and disease.Cell and tissue research · 2026Review
- Association between aspirin use and decline in intrinsic capacity among community-dwelling elderly: a study based on the Lianyungang ICOPE pilot project.Frontiers in medicine · 2026Article
- Recent advances in biomarkers for cardiac fibrosis.Frontiers in cardiovascular medicine · 2026Review
- Plasma biomarkers for monitoring muscle function and physical performance decline in older adults: A 2-year longitudinal study.The journal of nutrition, health & aging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAs society ages, identifying individuals at risk of sarcopenia becomes essential. Several plasma biomarkers are used to assess musculoskeletal status, but their results are inconsistent. Extracellular vesicles (EVs) are investigated as disease biomarkers due to their role in transporting molecules and influencing cellular processes. This study investigated the correlation of known sarcopenia biomarkers-adiponectin, myostatin, P3NP, CRP and TNF-α-measured from plasma-derived EVs with muscle mass, function and performance in an Osteoporosis Sarcopenia cohort at the Seoul National University Bundang Hospital.
methodsMuscle mass was evaluated by measuring appendicular skeletal muscle mass (ASM) using dual X-ray absorptiometry and calculated as ASM/height
resultsThe mean age of participants was 74.3 ± 12.1 years (range, 52.0-96.0), with 88.2% being female. Plasma-derived EV levels of myostatin and P3NP were significantly associated with walking speed (ꞵ = -0.309, p = 0.014) and SPPB (ꞵ = -0.276, p = 0.029), respectively. TNF-α levels were strongly correlated with hand grip strength (ꞵ = -0.313, p = 0.013). Using receiver-operating characteristic curve analysis, cutoff values for three factors were determined, allowing participants to be categorized into high and low groups. Low myostatin group had a higher hand grip strength (19.63 kg vs. 17.14 kg, p = 0.027) and faster five-time-sit-to-stand test times (17.34 s vs. 23.72 s, p = 0.032). Low P3NP levels showed a stronger grip strength (19.87 kg vs. 16.81 kg, p = 0.008), better SPPB scores (9.10 vs. 8.03, p = 0.006) and five-time-sit-to-stand times (18.31 s vs. 21.87 s, p = 0.002). Low TNF-α levels were linked to better walking speeds (0.82 m/s vs. 0.64 m/s, p = 0.009) and lower SARC-F scores (1.73 vs. 3.26, p = 0.029).
conclusionOur research confirmed that EVs-derived myostatin, P3NP and TNF-α are strongly associated with muscle function and performance. Significant differences in these factors between high and low groups based on biomarker cutoffs emphasize their diagnostic relevance for sarcopenia. These findings offer a promising avenue for identifying effective markers in future research and clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.